Efficacy of the Mirasol pathogen reduction technology system against severe fever with thrombocytopenia syndrome virus (SFTSV). Issue 4 (1st June 2015)

• Record Type: Journal Article
• Authors: Shinohara, N.; Matsumoto, C.; Chatani, M.; Uchida, S.; Yoshikawa, T.; Shimojima, M.; Satake, M.; Tadokoro, K.
• Is Part Of: Vox sanguinis. Volume 109:Issue 4(2015)
• Page Start: 417
• Page End: 419
• Publication Date: 2015-06-01
• Subjects: Blood -- Periodicals; Blood -- Transfusion -- Periodicals; Immunohematology -- Periodicals; Immunopathology -- Periodicals; 615.39
• DOI: 10.1111/vox.12305
• Languages: English
• ISSNs: 0042-9007

Abstract

<abstract abstract-type="main" id="vox12305-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Severe fever with thrombocytopenia syndrome virus (SFTSV) is a tickborne virus in the Bunyaviridae family. This virus has recently been found in China, Japan and Korea. The risk of transfusion‐transmitted SFTSV infection (TTI‐SFTSV) is a concern because person‐to‐person transmission resulting from contact with SFTSV‐contaminated blood has been reported. Therefore, we investigated the efficacy of the Mirasol pathogen reduction technology (PRT) system for inactivating SFTSV <italic>in vitro</italic>. The Mirasol PRT system achieved a &gt; 4·11 log₁₀ reduction value (LRV) for SFTSV. In conclusion, we showed that the Mirasol PRT system could potentially be used to reduce the risk of TTI‐SFTSV.</p> </abstract>